This Pill Will Change Cancer Treatment Forever
Revolution Medicines is the winner of the 2026 Gizmodo Science Fair for its research and development of Rasonque (daraxonrasib), the first approved cancer drug of its kind. The question Can we find an effective and reliable treatment for pancreatic cancer, which currently only has a five-year survival rate of 13%? The results In a large-scale clinical trial of 500 people with metastatic pancreatic ductal adenocarcinoma (the most common form of pancreatic cancer), people on daraxonrasib lived twice as long as those on standard chemotherapy: 13.2 months median survival compared to 6.7 months.
- ▪Revolution Medicines is the winner of the 2026 Gizmodo Science Fair for its research and development of Rasonque (daraxonrasib), the first approved cancer drug of its kind.
- ▪The question Can we find an effective and reliable treatment for pancreatic cancer, which currently only has a five-year survival rate of 13%?
- ▪The results In a large-scale clinical trial of 500 people with metastatic pancreatic ductal adenocarcinoma (the most common form of pancreatic cancer), people on daraxonrasib lived twice as long as those on standard chemotherapy: 13.2 month
Gizmodo files mainly under tech. We currently carry 1,470 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Gizmodo |
| Canonical URL | https://gizmodo.com/this-drug-will-change-cancer-treatment-forever-2000803542 |
| Publication time | Wed, 30 Sep 2026 11:08:28 +0000 |
| Retrieval time | 2026-09-30T11:12:01.292Z |
| Last seen | 2026-09-30T11:12:01.292Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | gbmd0p8jRnCc · 1 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Revolution Medicines is the winner of the 2026 Gizmodo Science Fair for its research and development of Rasonque (daraxonrasib), the first approved cancer drug of its kind. The question Can we find an effective and reliable treatment for pancreatic cancer, which currently only has a five-year survival rate of 13%? The results In a large-scale clinical trial of 500 people with metastatic pancreatic ductal adenocarcinoma (the most common form of pancreatic cancer), people on daraxonrasib lived twice as long as those on standard chemotherapy: 13.2 months median survival compared to 6.7 months. The treatment group also lived longer without progression of their cancer, and the drug was relatively well-tolerated, with only about 1% discontinuing the drug.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Gizmodo.
Discussion
0 commentsMore from Gizmodo
